First in man trials

From safety to efficacy

HAVING FINALISED our first in man trials. Our aim is to establish efficacy through Phase IIA Proof of Concept studies in one or more patient populations starting in Q4 2026.

2026 and beyond

Human PoC and exit

Securing financing for onwards journey
Initiation of phase IIa PoC study
Expansion of patent portfolio with process- and formulation patent applications
Preparations for exit with potential pharma partners

2025

Preparing for clinical proof of concept
Phase IIa PoC study aligned with KOLs and FDA

Pre-IND meeting with FDA
GMP process development and manufacturing
Submission and approval of CTA for phase IIa PoC study
Initiation of discussions with potential pharma partners post PoC
Expansion of patent portfolio with new patent applications

2020-2024

Safety and tolerability established

Toxicology studies to support clinical studies
Clinical safety and tolerability established in Phase I
Composition of matter patent granted in all major markets
NIH/NIDA grant of $2.5 million for preclinical investigations in opioid withdrawal syndrome (OWS)
EIC award of €17.5 million in blended funding

Until 2020

Establishment of the foundation

PN6047 developed and characterised
Pre-clinical proof of concept
Composition of matter patent applications filed in all major markets

Latest news

View all

April 17, 2026

Watch PharmNovo at LSX in Lisbon

Take the opportunity to listen to Per von Mentzer, CEO, presenting PN6047 at the LSX World Europe congress in Lisbon, March 2026. Learn how PharmNovo is shaping a new approach to pain relief with the goal to prove that powerful pain treatment doesn’t have to come with the cost of addiction. Discover how the company’s lead candidate PN6047, delivers effective pain relief without activating the mu-opioid receptor and avoiding the addiction risks associated with conventional opioids. The Phase II-ready Delta Opioid Receptor Agonist (DORA) with first-in-class potential, PN6047 represents a safer, non-addictive approach targeting a neuropathic pain market that is expected to double until 2033 and reach 13 bEUR.

April 9, 2026

Capsules ready for Phase IIa Study

PharmNovo is pleased to announce that that the company has completed drug product manufacturing for its lead candidate PN6047. This is an important milestone as the company prepares for its upcoming Phase IIa proof-of-concept study in neuropathic pain.

January 30, 2026

Welcome on Board

As the company prepares for the next phase of clinical development, the new Board composition strengthens our strategic capabilities ahead of Phase II development of our lead candidate, PN6047.

November 26, 2025

Endowed Chair awarded

We are delighted to share that Professor Amynah Pradhan has been awarded a prestigious Endowed Chair at Washington University, where she now serves as the Russell D. and Mary B. Shelden Professor of Anesthesiology.

NEXT: PHASE IIA-READY